Advertisement

von Willebrand Disease in the Pediatric and Adolescent Population

Published:October 11, 2010DOI:https://doi.org/10.1016/j.jpag.2010.08.005

      Abstract

      Recent studies indicate that bleeding disorders, particularly von Willebrand disease (VWD) is more prevalent than previously thought in adolescents with menorrhagia. Menorrhagia management in undiagnosed disorders of hemostasis may be associated with unwanted risks and complications. The prevalence of symptomatic VWD in the pediatric primary care setting appears to be 0.11% (95% CI, 0.04–0.25%). Studies evaluating the prevalence of VWD in adolescents with menorrhagia have included over 500 patients with a prevalence range from 3 to 36% depending on the clinical setting studied, with the highest prevalence seen in adolescents referred to an outpatient Hemophilia Center, while the lowest prevalence is seen in the acute hospital setting. Recently, the diagnosis of VWD has been facilitated by the use of pediatric bleeding questionnaires that have proved useful in quantifying the severity of bleeding symptoms. Treatment of VWD is often complex because a combination of therapies is often required. Potential treatment options include estrogen-progesterone preparations, desmopressin, antifibrinolytic agents and von Willebrand factor concentrates. More research is needed to evaluate the effectiveness of the various treatment modalities in the adolescent population.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Pediatric and Adolescent Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Von Willebrand E.A.
        Hereditar pseudohemofili.
        Fin Lakarsallsk Handl. 1926; 67: 87
        • Robertson J.
        • Lillicrap D.
        • James P.D.
        Von Willebrand disease.
        Pediatr Clin North Am. 2008; 55: 377
        • Kadir R.A.
        • Economides D.L.
        • Sabin C.A.
        • et al.
        Frequency of inherited bleeding disorders in women with menorrhagia.
        Lancet. 1998; 351: 485
        • Dilley A.
        • Drews C.
        • Miller C.
        • et al.
        von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia.
        Obstet Gynecol. 2001; 97: 630
        • Woo Y.L.
        • White B.
        • Corbally R.
        • et al.
        von Willebrand's disease: an important cause of dysfunctional uterine bleeding.
        Blood Coagul Fibrinolysis. 2002; 13: 89
        • Edlund M.
        • Blomback M.
        • von Schoultz B.
        • et al.
        On the value of menorrhagia as a predictor for coagulation disorders.
        Am J Hematol. 1996; 53: 234
        • Philipp C.S.
        • Dilley A.
        • Miller C.H.
        • et al.
        Platelet functional defects in women with unexplained menorrhagia.
        J Thromb Haemost. 2003; 1: 477
        • Kouides P.A.
        • Phatak P.D.
        • Burkart P.
        • et al.
        Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey.
        Haemophilia. 2000; 6: 643
        • Ragni M.V.
        • Bontempo F.A.
        • Hassett A.C.
        von Willebrand disease and bleeding in women.
        Haemophilia. 1999; 5: 313
        • Kirtava A.
        • Drews C.
        • Lally C.
        • et al.
        Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand's disease receiving care in haemophilia treatment centres: a case-control study.
        Haemophilia. 2003; 9: 292
        • Rodeghiero F.
        • Castaman G.
        • Dini E.
        Epidemiological investigation of the prevalence of von Willebrand's disease.
        Blood. 1987; 69: 454
        • Bowman M.
        • Hopman W.M.
        • Rapson D.
        • et al.
        The prevalence of symptomatic von Willebrand disease in primary care practice.
        J Thromb Haemost. 2010; 8: 213
        • Bowman M.
        • Hopman W.M.
        • Rapson D.
        • et al.
        A prospective evaluation of the prevalence of symptomatic von Willebrand disease (VWD) in a pediatric primary care population.
        Pediatr Blood Cancer. 2010; 55: 171
        • Bevan J.A.
        • Maloney K.W.
        • Hillery C.A.
        • et al.
        Bleeding disorders: A common cause of menorrhagia in adolescents.
        J Pediatr. 2001; 138: 856
        • Claessens E.A.
        • Cowell C.A.
        Acute adolescent menorrhagia.
        Am J Obstet Gynecol. 1981; 139: 277
        • Falcone T.
        • Desjardins C.
        • Bourque J.
        • et al.
        Dysfunctional uterine bleeding in adolescents.
        J Reprod Med. 1994; 39: 761
        • Jayasinghe Y.
        • Moore P.
        • Donath S.
        • et al.
        Bleeding disorders in teenagers presenting with menorrhagia.
        Aust N Z J Obstet Gynaecol. 2005; 45: 439
        • Kanbur N.O.
        • Derman O.
        • Kutluk T.
        • et al.
        Coagulation disorders as the cause of menorrhagia in adolescents.
        Int J Adolesc Med Health. 2004; 16: 183
        • Mikhail S.
        • Varadarajan R.
        • Kouides P.
        The prevalence of disorders of haemostasis in adolescents with menorrhagia referred to a haemophilia treatment centre.
        Haemophilia. 2007; 13: 627
        • Oral E.
        • Cagdas A.
        • Gezer A.
        • et al.
        Hematological abnormalities in adolescent menorrhagia.
        Arch Gynecol Obstet. 2002; 266: 72
        • Philipp C.S.
        • Faiz A.
        • Dowling N.
        • et al.
        Age and the prevalence of bleeding disorders in women with menorrhagia.
        Obstet Gynecol. 2005; 105: 61
        • Smith Y.R.
        • Quint E.H.
        • Hertzberg R.B.
        Menorrhagia in adolescents requiring hospitalization.
        J Pediatr Adolesc Gynecol. 1998; 11: 13
        • Tosetto A.
        • Rodeghiero F.
        • Castaman G.
        • et al.
        A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD).
        J Thromb Haemost. 2006; 4: 766
        • Rodeghiero F.
        • Castaman G.
        • Tosetto A.
        • et al.
        The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study.
        J Thromb Haemost. 2005; 3: 2619
        • Woods A.I.
        • Meschengieser S.S.
        • Blanco A.N.
        • et al.
        Clinical features and laboratory patterns in a cohort of consecutive Argentinian patients with von Willebrand's disease.
        Haematologica. 2001; 86: 420
        • Mauser Bunschoten E.P.
        • van Houwelingen J.C.
        • Sjamsoedin Visser E.J.
        • et al.
        Bleeding symptoms in carriers of hemophilia A and B.
        Thromb Haemost. 1988; 59: 349
        • Sramek A.
        • Eikenboom J.C.
        • Briet E.
        • et al.
        Usefulness of patient interview in bleeding disorders.
        Arch Intern Med. 1995; 155: 1409
        • Nosek-Cenkowska B.
        • Cheang M.S.
        • Pizzi N.J.
        • et al.
        Bleeding/bruising symptomatology in children with and without bleeding disorders.
        Thromb Haemost. 1991; 65: 237
        • Bowman M.
        • Mundell G.
        • Grabell J.
        • et al.
        Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease.
        J Thromb Haemost. 2008; 6: 2062
        • Bowman M.
        • Riddel J.
        • Rand M.L.
        • et al.
        Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire.
        J Thromb Haemost. 2009; 7: 1418
        • Biss T.T.
        • Blanchette V.S.
        • Clark D.S.
        • et al.
        Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire.
        J Thromb Haemost. 2010; 8: 950
        • Abildgaard C.F.
        • Suzuki Z.
        • Harrison J.
        • et al.
        Serial studies in von Willebrand's disease: variability versus "variants.
        Blood. 1980; 56: 712
        • Nichols W.L.
        • Hultin M.B.
        • James A.H.
        • et al.
        von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).
        Haemophilia. 2008; 14: 171
        • James A.H.
        • Kouides P.A.
        • Abdul-Kadir R.
        • et al.
        Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel.
        Am J Obstet Gynecol. 2009; 201: 12.e1
        • Kadir R.A.
        • Economides D.L.
        • Sabin C.A.
        • et al.
        Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive.
        Thromb Haemost. 1999; 82: 1456
        • Mandalaki T.
        • Louizou C.
        • Dimitriadou C.
        • et al.
        Variations in factor VIII during the menstrual cycle in normal women.
        N Engl J Med. 1980; 302: 1093
        • Miller C.H.
        • Dilley A.B.
        • Drews C.
        • et al.
        Changes in von Willebrand factor and factor VIII levels during the menstrual cycle.
        Thromb Haemost. 2002; 87: 1082
        • Bohm M.
        • Taschner S.
        • Kretzschmar E.
        • et al.
        Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease.
        Blood Coagul Fibrinolysis. 2006; 17: 39
        • Lipton R.A.
        Misdiagnosis by milk box.
        Haemophilia. 2003; 9: 235
        • Sadler J.E.
        • Budde U.
        • Eikenboom J.C.
        • et al.
        Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.
        J Thromb Haemost. 2006; 4: 2103
        • James P.D.
        • Paterson A.D.
        • Notley C.
        • et al.
        Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study.
        J Thromb Haemost. 2006; 4: 783
        • Eikenboom J.
        • Van Marion V.
        • Putter H.
        • et al.
        Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD.
        J Thromb Haemost. 2006; 4: 774
        • Lethagen S.
        • Hillarp A.
        • Ekholm C.
        • et al.
        Distribution of von Willebrand factor levels in young women with and without bleeding symptoms: influence of ABO blood group and promoter haplotypes.
        Thromb Haemost. 2008; 99: 1013
        • Gill J.C.
        • Endres-Brooks J.
        • Bauer P.J.
        • et al.
        The effect of ABO blood group on the diagnosis of von Willebrand disease.
        Blood. 1987; 69: 1691
        • Sidonio Jr., R.F.
        • Smith K.J.
        • Ragni M.V.
        Cost-utility analysis of von Willebrand disease screening in adolescents with menorrhagia.
        J Pediatr. 2010 Sep; 157 (460.e1. Epub 2010 May 6): 456-460
        • Rodeghiero F.
        • Castaman G.
        • Tosetto A.
        How I treat von Willebrand disease.
        Blood. 2009; 114: 1158
        • Federici A.B.
        • Mannucci P.M.
        Management of inherited von Willebrand disease in 2007.
        Ann Med. 2007; 39: 346
        • Franchini M.
        The use of desmopressin as a hemostatic agent: a concise review.
        Am J Hematol. 2007; 82: 731
        • Rainsford S.G.
        • Jouhar A.J.
        • Hall A.
        Tranexamic acid in the control of spontaneous bleeding in severe haemophilia.
        Thromb Diath Haemorrh. 1973; 30: 272
        • Fraser I.S.
        • Porte R.J.
        • Kouides P.A.
        • et al.
        A benefit-risk review of systemic haemostatic agents: part 2: in excessive or heavy menstrual bleeding.
        Drug Saf. 2008; 31: 275
        • Rodeghiero F.
        • Castaman G.
        • Mannucci P.M.
        Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A.
        Thromb Haemost. 1996; 76: 692
        • Bertholini D.M.
        • Butler C.S.
        Severe hyponatraemia secondary to desmopressin therapy in von Willebrand's disease.
        Anaesth Intensive Care. 2000; 28: 199
        • Kavanagh G.M.
        • Sansom J.E.
        • Harrison P.
        • et al.
        Tranexamic acid (Cyklokapron)-induced fixed-drug eruption.
        Br J Dermatol. 1993; 128: 229
        • Lucas-Polomeni M.M.
        • Delaval Y.
        • Menestret P.
        • et al.
        A case of anaphylactic shock with tranexamique acid (Exacyl).
        Ann Fr Anesth Reanim. 2004; 23: 607
        • Mannucci P.M.
        • Lusher J.M.
        Desmopressin and thrombosis.
        Lancet. 1989; 2: 675
        • Byrnes J.J.
        • Larcada A.
        • Moake J.L.
        Thrombosis following desmopressin for uremic bleeding.
        Am J Hematol. 1988; 28: 63
        • Grainge C.
        • Nokes T.
        Cerebral arterial thrombosis in a young woman following vasopressin for von Willebrand's disease.
        Thromb Haemost. 2005; 93: 380
        • Woo K.S.
        • Tse L.K.
        • Woo J.L.
        • et al.
        Massive pulmonary thromboembolism after tranexamic acid antifibrinolytic therapy.
        Br J Clin Pract. 1989; 43: 465
        • Taparia M.
        • Cordingley F.T.
        • Leahy M.F.
        Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia.
        Eur J Haematol. 2002; 68: 307
        • Lindoff C.
        • Rybo G.
        • Astedt B.
        Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
        Thromb Haemost. 1993; 70: 238
        • Berntorp E.
        • Follrud C.
        • Lethagen S.
        No increased risk of venous thrombosis in women taking tranexamic acid.
        Thromb Haemost. 2001; 86: 714
        • Kadir R.A.
        • Lee C.A.
        • Sabin C.A.
        • et al.
        DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study.
        Haemophilia. 2002; 8: 787
        • Leissinger C.
        • Becton D.
        • Cornell Jr., C.
        • et al.
        High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A.
        Haemophilia. 2001; 7: 258
        • Mannucci P.M.
        Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years.
        Blood. 1997; 90: 2515
        • Mannucci P.M.
        • Canciani M.T.
        • Rota L.
        • et al.
        Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease.
        Br J Haematol. 1981; 47: 283
        • Rodeghiero F.
        • Castaman G.
        • Di Bona E.
        • et al.
        Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A.
        Blood. 1989; 74: 1997
        • Rose S.S.
        • Faiz A.
        • Miller C.H.
        • et al.
        Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction.
        Haemophilia. 2008; 14: 571
        • Dunn A.L.
        • Powers J.R.
        • Ribeiro M.J.
        • et al.
        Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients.
        Haemophilia. 2000; 6: 11
        • Amesse L.S.
        • Pfaff-Amesse T.
        • Leonardi R.
        • et al.
        Oral contraceptives and DDAVP nasal spray: patterns of use in managing vWD-associated menorrhagia: a single-institution study.
        J Pediatr Hematol Oncol. 2005; 27: 357
        • Mannucci P.M.
        Hemostatic drugs.
        N Engl J Med. 1998; 339: 245
        • Kouides P.A.
        • Byams V.R.
        • Philipp C.S.
        • et al.
        Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid.
        Br J Haematol. 2009; 145: 212
      1. Tranexamic acid (Lysteda) for treatment of menorrhagia.
        Med Lett Drugs Ther. 2010; 52: 54
        • Siegbahn A.
        • Odlind V.
        • Hedner U.
        • et al.
        Coagulation and fibrinolysis during the normal menstrual cycle.
        Ups J Med Sci. 1989; 942: 137
        • Foster P.A.
        The reproductive health of women with von Willebrand Disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH.
        Thromb Haemost. 1995; 74: 784
        • Berntorp E.
        • Petrini P.
        Long-term prophylaxis in von Willebrand disease.
        Blood Coagul Fibrinolysis. 2005; : S23
        • Berntorp E.
        • Abshire T.
        von Willebrand Disease Prophylaxis Network Steering Committee. The von Willebrand disease prophylaxis network: exploring a treatment concept.
        J Thromb Haemost. 2006; 4: 2511
        • Goudemand J.
        • Scharrer I.
        • Berntorp E.
        • et al.
        Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods.
        J Thromb Haemost. 2005; 3: 2219
        • Borel-Derlon A.
        • Federici A.B.
        • Roussel-Robert V.
        • et al.
        Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients.
        J Thromb Haemost. 2007; 5: 1115
        • Mannucci P.M.
        • Franchini M.
        • Castaman G.
        • et al.
        Italian Association of Hemophilia Centers: Evidence-based recommendations on the treatment of von Willebrand disease in Italy.
        Blood Transfus. 2009; 7: 117
        • Mannucci P.M.
        • Moia M.
        • Rebulla P.
        • et al.
        Correction of the bleeding time in treated patients with severe von Willebrand disease is not solely dependent on the normal multimeric structure of plasma von Willebrand factor.
        Am J Hematol. 1987; 25: 55
        • Castillo R.
        • Monteagudo J.
        • Escolar G.
        • et al.
        Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients.
        Blood. 1991; 77: 1901